Gracell Biotechnologies Inc. has closed a $100 million series C financing round to advance its CAR T-cell therapy candidates, including autologous product candidate, GC-012F, and allogeneic product candidate, GC-027. Both candidates are in investigator-initiated phase I trials in China.
Gracell Biotechnologies Inc. has closed a $100 million series C financing round to advance its CAR T-cell therapy candidates, including autologous product candidate, GC-012F, and allogeneic product candidate, GC-027. Both candidates are in investigator-initiated phase I trials in China.
Crispr Therapeutics AG's first stab at developing an allogeneic CAR T-cell therapy, CTX-110, looks promising, but the efficacy data were overshadowed by a death in the study.
HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.
HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.
PERTH, Australia – Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy.
PERTH, Australia – Sydney-based Chimeric Therapeutics Ltd. has acquired exclusive worldwide rights to develop and commercialize the City of Hope Cancer Center’s chlorotoxin chimeric antigen receptor cell therapy that uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma.
Fosun Kite Biotechnology Co. Ltd. secured another $20 million investment from Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Kite Pharma Inc., which each contributed $10 million.
Two California companies – Nkarta Inc. and Poseida Therapeutics Inc. – scored impressive IPOs but with decidedly different post-pricing performance, as Wall Street showed its enthusiasm for the former’s natural killer (NK) cell research by pushing shares (NASDAQ:NKTX) up 166%, to close July 10 at $47.90, an increase of $29.90.
Shanghai-based Fosun Kite Biotechnology Co. Ltd. secured another $20 million investment from Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Kite Pharma Inc., which each contributed $10 million. The fund will support further clinical trials and manufacturing of its CAR T candidates, including FKC-876, which looks likely to become the first CAR T therapy approved in China.
RSS
